Glycemic control, maternal and neonatal outcomes in gestational diabetes mellitus treated with regular aspart insulin in comparison with regular human insulin

Faima Khatun; Khadiza Akter; Umme Sakia Kauser; Soma Bagche; Moumita Ghosh Rupa; Ashrafi Yasmin; Shahrina Alam

doi:10.18203/2320-1770.ijrcog20263418

Authors

Faima Khatun Department of Obstetrics and Gynecology, BRB Hospitals Limited, Dhaka, Bangladesh
Khadiza Akter Department of Obstetrics and Gynaecology, United Healthcare Services Limited, Dhaka, Bangladesh
Umme Sakia Kauser Directorate General of Health Services (DGHS), Dhaka, Bangladesh
Soma Bagche Department of Obstetrics and Gynaecology, Khulna Medical College Hospital, Khulna, Bangladesh
Moumita Ghosh Rupa Department of Obstetrics and Gynaecology, 250 Bedded General Hospital, Jashore, Bangladesh
Ashrafi Yasmin Department of Obstetrics and Gynaecology, Dhaka Medical College Hospital, Dhaka, Bangladesh
Shahrina Alam Department of Obstetrics and Gynaecology, BIRDEM Academy, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20263418

Keywords:

Gestational diabetes mellitus, Insulin aspart, Regular human insulin, Fasting blood glucose, Neonatal hypoglycaemia

Abstract

Background: Gestational diabetes mellitus (GDM) is associated with adverse maternal and neonatal outcomes, making optimal glycemic control essential during pregnancy. Rapid-acting insulin analogues may provide better postprandial glucose control than regular human insulin. This study aimed to compare glycemic control and maternal and neonatal outcomes among women with GDM treated with regular aspart insulin versus regular human insulin.

Methods: This randomized controlled trial was conducted at the outpatient Department of Obstetrics and Gynaecology, BIRDEM General Hospital, Dhaka, from October 2023 to January 2025. A total of 102 women diagnosed with GDM after 24 weeks' gestation were randomly assigned to receive regular aspart insulin (Group I, n=54) or regular human insulin (Group II, n=48). Follow-up was performed at 28-, 32- and 36-weeks’ gestation and after delivery. Ninety-five participants completed follow-up (49 and 46, respectively). Fasting blood sugar (FBS), HbA1c, birth weight and maternal and neonatal outcomes were compared. Statistical significance was set at p<0.05.

Results: Group I achieved significantly lower FBS than Group II at 28, 32 and 36 weeks' gestation and postpartum (all p<0.0001). HbA1c and birth weight were comparable between groups. Maternal complications did not differ significantly. Neonatal hypoglycaemia occurred less frequently in Group I than Group II (6.1% vs 19.6%, p=0.048).

Conclusion: Regular aspart insulin provided superior fasting glycemic control and reduced neonatal hypoglycaemia compared with regular human insulin, without increasing maternal complications, supporting its use as an effective treatment option for GDM.

References

Huhn EA, Linder T, Eppel D, Weißhaupt K, Klapp C, Schellong K, et al. Effectiveness of real-time continuous glucose monitoring to improve glycaemic control and pregnancy outcome in patients with gestational diabetes mellitus: a study protocol for a randomised controlled trial. BMJ Open. 2020;10(11):40498.

Koivunen S, Viljakainen M, Männistö T, Gissler M, Pouta A, Kaaja R, et al. Pregnancy outcomes according to the definition of gestational diabetes. PLoS One. 2020;15(3):229496.

You JY, Choi SJ, Roh CR, Kim JH, Oh SY. Pregnancy and neonatal outcomes in gestational diabetes treated with regular insulin or fast-acting insulin analogues. Gynecol Obst. 2016;81(3):232-7.

Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):3342.

Ray A. Introductory Chapter: Gestational. Gestational Diabetes Mellitus: An Overview with Some Recent Advances. 2020.

Mecacci F, Carignani L, Cioni R, Bartoli E, Parretti E, La Torre P, et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. European J Obst Gynecol Reprod Biol. 2003;111(1):19-24.

Blum AK. Insulin use in pregnancy: an update. Diabetes Spectrum. 2016;29(2):92-7.

Mathiesen ER, Damm P. Pregnancy–pharmacological problems. in pharmacotherapy of diabetes: new developments: improving life and prognosis for diabetic patients 2007: 249-254.

Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, et al. Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial. Diabetes Care. 2017;40(7):951-7.

Ghosh A. Efficacy and safety of faster aspart in comparison to insulin aspart among Indian women with gestational diabetes. Current Diabetes Rev. 2023;19(8):24-30.

Misra S, Mathieu C. Are newer insulin analogues better for people with Type 1 diabetes. Diab Med. 2020;37(4):522-31.

Begum R, Roy S, Banik S. The prevalence of gestational diabetes mellitus in Bangladesh: a systematic review and meta-analysis. Int J Diab Dev Countries. 2022;42(4):606-13.

Pooransari P, Ebrahimi A, Mirzamoradi M, Ketabdar M. A comparison of the efficacy of insulin aspart and regular insulin for managing gestational diabetes and their effects on delivery outcomes.

Wang X, Zhang S, Yu W, Li G, Li J, Ji J, Mi Y, Luo X. Pre-pregnancy body mass index and glycated-hemoglobin with the risk of metabolic diseases in gestational diabetes: a prospective cohort study. Front Endocrinol. 2023;12:38873.

Abraham T, Romani AM. The relationship between obesity and pre-eclampsia: incidental risks and identification of potential biomarkers for pre-eclampsia. Cells. 2022;11(9):1548.

Lewandowska M, Więckowska B, Sajdak S, Lubiński J. Pre-pregnancy obesity vs. other risk factors in probability models of preeclampsia and gestational hypertension. Nutrients. 2020;12(9):2681.

Macura M, Dugalic S, Todorovic J, Gutic B, Milincic M, Bozic D, Stojiljkovic M, Micic J, Gojnic M. Prenatal monitoring of pregnancies complicated by diabetes mellitus. Sanamed. 2022;17(3):195-201.

Rosenfeld E, Thornton PS. Hypoglycemia in neonates, infants and children. Endotext. 2023;6:76.

Nørgaard SK, Søholm JC, Mathiesen ER, Nørgaard K, Clausen TD, Holmager P, et al. Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial. Lancet Diab Endocrinol. 2023;11(11):811-21.

Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med. 2007;24(10):1129-35.